Airna Raises $60M to Advance RNA Therapeutics

Airna Raises $60M in Financing Round

Airna (Linkedin), a leading biotech company in the United States, has successfully closed a $60 million financing round, bringing their total Series A funding to $90 million. With a focus on RNA editing therapeutics, Airna is poised to make significant advancements in the treatment of rare and common genetic disorders.

Funding Amount: $60 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Kris Elverum (CEO Linkedin)

What Airna needs to buy: Airna is seeking partnerships with clinical research organizations (CROs) for conducting clinical trials, as well as collaborations with biotech manufacturers to support the production of their RNA therapeutics. Additionally, marketing and outreach services are needed to enhance their market presence and educate healthcare providers about their innovative therapies. Companies specializing in clinical research, biotech manufacturing, and healthcare marketing should consider Airna as a potential partner.